Page 6 - Vasoclick emagazine_issue 1_Neat

week 4.
follow-up. Anti-Clot Treatment Scale (ACTS)
treatment option for patients with CAT, because
9
The common reasons for shifting to rivaroxaban
questionnaires were performed at baseline, week
it can be administered to patients as a fixed oral
were mainly patient-related that were dependent
dose and without any requirement of routine
4, and months 3 and 6 for pairwise comparison
on their preferences and desires, as summarized
Following a shift to rivaroxaban, there was a
to mean scores at baseline (Figure 1).
anticoagulation monitoring.
8
in table 1.
significant improvement in patient treatment
8
Cancer-associated thrOmboSIs –
Study outcome:
satisfaction on the ACTS Burdens subscale at
patient-reported outcoMes with rivarOx-
week 4 and maintained at months 3 and 6.
1) Percentage of patients who switched to
aban (COSIMO) study:
The immediate increase in treatment
Rivaroxaban from other therapies
The COSIMO study was designed to evaluate
satisfaction at week 4 is strongly supportive
Majority of patients changed to Rivaroxaban
patient satisfaction after planned change from
of treatment dependent nature of the change
from LMWH therapy (96.65%), while few patients
traditional anticoagulant therapy to rivaroxaban
in satisfaction.
changed from VKA and Fondaparinux as well
therapy for cancer associated thrombosis
(Figure 2).
8
(CAT).
8, 9
treatment of CAT owing to superior efficacy and
Factors underlying cancer associated
The COSIMO study demonstrates that CAT
safety. The major drawbacks associated with
4, 5
thrombosis (CAT)
patients who changed their VTE treatment to
VKA include strict requirement of monitoring of
Study plan:
Cancer promotes hypercoagulability in patients
Rivaroxaban experienced :
8
international normalized ratio (INR) to track
A prospective, non-interventional, single-arm
improved
due to some or all of the following factors :
3
anticoagulation status and interactions with food
cohort study enrolled patients from 55 sites
everyday clinical practice.
Long-term chemotherapy
and drugs.
4,5
across Australia, Canada and Europe. 505
8,9
reduced anticoagulation burden (patient
Endothelial damage
cancer patients who received rivaroxaban were
reported).
However, patients’ adherence towards LMWH
included in the study. During analysis, ratings
6
Obstruction to blood flow by tumor masses
3) Patient-reported treatment satisfaction on
This can improve long term persistence and
over oral anticoagulants is low thereby affecting
were reverse coded; as a result, higher scores
Procoagulant microparticles released from
the ACTS Burdens subscale after switching to
clinical outcomes.
patient outcomes. Major reasons are as follows :
4
reflected greater patient treatment satisfaction.
8
cancer cells
Rivaroxaban :
8
Observations lasted for 6 months or until the
Comorbid conditions
References
Inconvenient intravenous infusion requires
participant withdrew consent, died, or was lost to
a) At Baseline:
Advanced age
recurrent hospital visits and clinical care
1) Agnelli G, Verso M. Management of venous
ACTS burden score was 51.8 out of 60
thromboembolism in patients with cancer. J Thromb
Restricted mobility
High treatment cost
Haemost. 2011;9:316-324.
doi:10.1111/j.1538-7836.2011.04346.x
b) At Week 4:
Management of VTE in cancer patients
Recently the international guidelines have been
2) Blom JW, Vanderschoot JP, Oostindi r MJ, Osanto S,
Patients who remained in the study:
van der Meer FJ, Rosendaal FR. Incidence of venous
Due to high VTE recurrence risk in patients with
updated to include recommendations for DOACs
thrombosis in a large cohort of 66,329 cancer patients:
ACTS Burden score was significantly higher
results of a record linkage study. J Thromb Haemost.
CAT, especially in the first 6 months, extended
in patients with cancer and VTE. The American
4,5
2006;4(3):529-535.
(55.6 out of 60).
anticoagulation therapy has been recommended
Society of hematology (ASH) 2021 guidelines
doi:10.1111/j.1538-7836.2006.01804.x
in
treatment
Significant
increase
if the bleeding risk is low.
recommend the use of direct oral anticoagulants
4,5
3) Campello E, Henderson MW, Noubouossie DF, Simioni
satisfaction.
P, Key NS. Contact system activation and cancer: new
(DOACs) for the short term treatment of VTE in
insights in the pathophysiology of cancer-associated
The
previous
active cancer over low molecular weight heparin
guidelines
included
thrombosis. Thromb Haemost. 2018;118 (2):251-265.
c) At 3 months and 6 months:
doi:10.1160/TH17-08-05962014.59.7351
(LMWH).
low-molecular-weight heparin (LMWH) based
6
The ACTS Burden score was 56.2 and 56.5 out
4) Key NS, Khorana AA, Kuderer NM, et al. Venous
therapy
anticoagulation
vitamin
K
over
thromboembolism prophylaxis and treatment in patients
of 60 at 3 and 6 months, respectively.
Rivaroxaban is a promising and convenient
antagonists (VKAs) for the initial and long-term
with cancer: ASCO clinical practice guideline update. J
The results were statistically significant as in
Clin Oncol. 2020;38:496-520.
Endovascular repair versus open surgical repair of juxtarenal abdominal aortic aneurysms: short-term 8 2) Reasons for switching to rivaroxaban Conclusion 8 treatment satisfaction 8 in
postoperative outcomes and mortality 05
5) National Comprehensive Cancer Network.
Cancer-associated venous thromboembolic disease,
Version 1.2020. National Comprehensive Cancer Network, Surgery
Inc.; 2020. Available at: https://www.nccn.org/profession
als/physi cian_gls/pdf/vte.pdf [accessed 22 March 2022]. Endovascular repair versus open surgical repair of juxtarenal abdominal aortic
aneurysms: short-term postoperative outcomes and mortality
6) Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK,
Khorana AA, Leavitt AD, Lee AY, Macbeth F, Morgan RL,
Noble S. American Society of Hematology 2021 Endorsed by: Dr. Sunder Narasimhan, Senior Vascular Consultant, Bangalore
guidelines for management of venous thromboembolism:
prevention and treatment in patients with cancer. Blood Background
Adv. 2021; 5(4):927-974.
doi:10.1182/bloodadvances.2020003442 Endovascular aneurysm repair (EVAR) is a highly preferred and widely implemented method to treat
abdominal aortic aneurysms (AAAs) because it is minimally invasive and causes less mortality. 1
7) Yeh CH, Hogg K, Weitz JI. Overview of the new oral
anticoagulants: opportunities and challenges. Arterioscler
Thromb Vasc Biol. 2015;35:1056-1065.
Juxtarenal abdominal aortic aneurysm (JRAAA) extends up to the renal arteries but does not include
8) Cohen AT, Maraveyas A, Beyer-Westendorf J, Lee AY, them (i.e., a short infrarenal aortic neck <10 mm). JRAAAs therefore often require inter-renal,
Folkerts K, Abdelgawwad K, De Sanctis Y, Fatoba S,
Bamber L, Bach M, Mantovani LG. Patient-reported suprarenal below the superior mesentery artery, or infra- or supracoeliac clamping. 2,3
outcomes associated with changing to rivaroxaban for
the treatment of cancer-associated venous
thromboembolism–The COSIMO study. Thromb Res. In patients with elective infrarenal aneurysms, EVAR has been reported to confer a short-term survival
2021; 206; 1-4. doi: 10.1016/j.thromres.2021.06.021
advantage compared to open surgical repair (OSR). 4
9) Maraveyas A, Beyer-Westendorf J, Lee AY, et al.
Cancer-Associated ThrOmboSIs - Patient-Reported
OutcoMes With RivarOxaban (COSIMO) - Baseline However, the findings of infrarenal aneurysms cannot be directly extrapolated to JRAAAs repair as
characteristics and clinical outcomes. Res Pract Thromb
Haemost. 2021;5(8):e12604. doi:10.1002/rth2.12604 their surgery requires a distinct approach in OSR involving suprarenal clamping. When treated with
complex endovascular aneurysm repair (cEVAR), patients have to undergo branch inclusion during
reconstruction (chimney EVAR [CHEVAR] or fenestrated EVAR [FEVAR]. Thus, outcomes may be
different than those of the infrarenal aneurysms. 5, 6
JRAAAs account for roughly 15% of all AAAs, however limited clinical evidence is available regarding
outcomes of JRAAA repair. 5
Thus, this study evaluated the most recent short-term outcomes after elective juxtarenal aortic repair
in patients reflecting daily practice in The Netherlands. This was a multicenter retrospective study
6
analyzing prospectively collected data of the Dutch Surgical Aneurysm Audit (DSAA), a mandatory
nationwide audit for all patients treated for an aortic aneurysm in The Netherlands. (Figure 1)
7
Figure 1: Patient selection for multiple retrospective study of the Dutch Surgical Aneurysm Audit 6
OSR- 258 patients
455 electively and primarily
treated patients with JRAAAs
cEVAR- 197 patients